Cyrus Harmon - Apr 30, 2024 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Role
Director
Signature
/s/ Shane Kovacs, Attorney-in-Fact
Stock symbol
OLMA
Transactions as of
Apr 30, 2024
Transactions value $
-$142,650
Form type
4
Date filed
5/2/2024, 05:09 PM
Previous filing
Mar 29, 2024
Next filing
May 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OLMA Common Stock Sale -$143K -15K -1.82% $9.51 811K Apr 30, 2024 Direct F1, F2
holding OLMA Common Stock 122K Apr 30, 2024 See Footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.
F2 The weighted average sale price for the transaction reported was $9.51, and the range of prices was between $9.20 and $9.91. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F3 The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.